OncoZenge AB (publ) announces today that a positive opinion has been received regarding the patentability of the new international application submitted to the PCT (Patent Cooperation Treaty) earlier ...

The UK’s trailing productivity growth rate relative to other G7 economies has prompted policymakers to give a lot of attention to long-term sickness – in reality however, 80% of absences are due to ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, today announced that Matthew Sleeman, PhD, has been ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company's management will participate in ...

Alithia Life Sciences, a full-service Contract Research Organization (CRO) committed to delivering high-quality clinical ...

The global Stem Cell Assays Market is experiencing unprecedented growth, driven by advancements in regenerative medicine, ...

The global Influenza Diagnostics Market is on a growth trajectory, driven by increasing influenza prevalence, advancements in diagnostic technologies, and rising awareness of early detection. Valued ...

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., ...

Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of the Sync Badge, a hands-free, wearable device designed to enhance communication and collaboration in the fast-paced ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent ...